NCI-H2452 Cells

The NCI-H2452 cell line is a human malignant pleural mesothelioma cell line, which was derived from the pleura of a patient with mesothelioma. It is frequently used in research focused on understanding mesothelioma pathophysiology and developing new therapeutic approaches. Like other mesothelioma cell lines, NCI-H2452 is associated with exposure to asbestos fibers, a well-established risk factor for mesothelioma. Studies involving NCI-H2452 have highlighted its utility in exploring mechanisms of disease progression and response to various therapies, particularly gene therapies and viral oncolysis approaches.

NCI-H2452 cells express Coxsackie and adenovirus receptor (CAR) and CD46, which makes them suitable candidates for adenovirus-based gene therapy studies. In research investigating oncolytic virotherapy, both adenovirus type 5 (Ad5) and a fiber-modified variant (Ad5F35) have been tested on NCI-H2452 cells. These adenoviruses replicate selectively within tumor cells, inducing oncolysis in a viral particle-dependent manner. It was found that both Ad5 and Ad5F35 displayed similar efficacy in inducing cell death in NCI-H2452 cells, supporting their potential in gene therapy for malignant mesothelioma.

In addition to its role in oncolytic virotherapy, NCI-H2452 cells have been used to study tumor angiogenesis, a key factor in mesothelioma progression. NCI-H2452 expresses progranulin (PGRN) and granulin-like proteins, which have been identified as novel angiogenic factors that operate independently of the VEGF pathway. This VEGF-independent angiogenesis is crucial, as it offers alternative therapeutic targets in cases where anti-VEGF therapies like bevacizumab fail to improve patient outcomes. Research indicates that these granulins contribute significantly to the formation of new blood vessels, which supports tumor growth and may be involved in the resistance to certain treatments.